Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Avirmax Biopharma Inc. to Exhibit Development of Next Generation Gene Therapies for Ocular Diseases at the AAO 2024 Annual Meeting in Chicago


HAYWARD, Calif., Oct. 15, 2024 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI) team will attend AAO 2024, the American Academy of Ophthalmology's annual meeting in Chicago, October 17-21, 2024. Avirmax will exhibit at booth #5357 to showcase the latest progress of the ABI gene therapy ocular programs.

Avirmax Biopharma Is Unlocking Potential of Genetic Medicine, Preserving Vision for Millions of Patients

With a mission of unlocking the great potential of AAV based genetic medicine for treating retinal diseases, Avirmax Biopharma has innovated proprietary AAV2.N54 capsids optimized for superior gene delivery to the macula retina on basis of AAV2, with safe intravitreal administration aims to provide a long-lasting therapeutic effect and potentially reduces the need for frequent intravitreal injections. Manufacturing at Avirmax's in-house cGMP facility using proprietary VSaftm virus free Sf9 cell lines enable product safety and cost of gene therapy vector production to be 5-10% of the traditional approaches, unlocking a great potential for the next generation genetic medicines be made accessible to millions of retinal patients worldwide.

"Avirmax Biopharma's innovative pipeline products focus on many ophthalmic unmet needs," said Chief Medical Officer, Wendy Murahashi, MD.

Avirmax Biopharma's lead candidate ABI-110 for wet AMD including PCV ? currently enrolling patients for Phase I/IIa trials in the US (https://clinicaltrials.gov/study/NCT06550011) ? showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. The ABI-201 programs for geographic atrophy (GA), dry AMD, proliferative diabetic retinopathy (PDR), and the ABI-902 pipeline targeting multiple types of glaucoma are currently under nonclinical development.

About Avirmax Inc.
Avirmax Biopharma, Inc., based in the San Francisco Bay Area, is a clinical stage biopharmaceutical company developing next-generation gene therapies for wet AMD, PCV, dry AMD, glaucoma and diabetic retinopathy. Utilizing proprietary AAV vector technologies, Avirmax Biopharma aims to deliver safe, effective, and accessible gene therapies to improve patient outcomes and preserve vision. Visit us at avirmax.com for more information.

Contact
June Song, Associate Director for Operations
Email: [email protected]
Tel: +1-510-641-0201

Address
25503 Whitesell Street
Hayward 94545 CA
USA

SOURCE Avirmax


These press releases may also interest you

at 21:15
Global IT company FPT has recently entered into a three-year partnership agreement with OutSystems, a recognized leader in high-performance application development. Through this collaboration, FPT will become one of Outystems's reseller and delivery...

at 21:00
KLEVV, the leading consumer memory and storage brand introduced by Essencore, is excited to announce the launch of its brand-new URBANE V RGB DDR5 Gaming/OC memory. Ideal for advanced content creation and professional gaming. Sleek Design with...

at 21:00
- On the second day of the SK AI Summit 2024, SK Telecom introduced Aster(A*), an AI-driven personal assistant designed for global users - Aster is designed as an 'Agentic AI,' which goes beyond answering simple queries by understanding user...

at 20:41
HTX Ventures, the global investment division of HTX, today unveils its latest research on crypto and its impact on the much anticipated U.S. presidential election. This marks the first time that crypto has become a key issue in a U.S. election, and...

at 20:00
NTT DATA, a global leader in digital business and IT services, today announced the expansion of its strategic partnership with Google Cloud to accelerate the adoption of cloud-based data analytics and generative AI solutions for customers across key...

at 19:55
Questor Technology Inc. ("Questor", the "Company"), would like to announce Mr. Quentin Kyliuk is no longer with Questor Technology Inc., effective October 28, 2024. On behalf of the employees and Board of Directors, the Company thanks Quentin...



News published on and distributed by: